Dr Agarwals Eye Hospital DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.75×	0.77×	0.74×	0.75×
	0.94×	0.89×	0.97×	0.91×
	21.2%	19.9%	20.2%	20.3%
	0.68×	0.72×	0.72×	0.76×
	2.21×	2.93×	3.15×	3.44×
	22.4%	29.0%	33.0%	36.0%
	25.2%	29.8%	34.3%	38.6%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

DRAGARWQ₹5,299.50

Dr Agarwals Eye Hospital Limited

· Pharma & Health

₹ CrorePeersKMCSHIL KOVAI LOTUSEYE GPTHEALTH GKSL SHALBY INDRAMEDCO ARTEMISMEDMcap ₹2,527 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.75	0.74	0.77	0.75
Interest Burden (Pretax/EBIT) ×	0.91	0.97	0.89	0.94
EBIT Margin %	20.35	20.18	19.90	21.17
Asset Turnover ×	0.76	0.72	0.72	0.68
Financial Leverage (Assets/Equity) ×	3.44	3.15	2.93	2.21
ROE (5-step product, year-end total equity) %	36.04	32.98	28.99	22.41
ROE (owners' profit / average owners' equity) %	38.56	34.28	29.80	25.22

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.